Mrs. Elizabeth Verdell Walter, MED, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 361 Shallowford Dr, Boiling Springs, SC 29316 Phone: 864-814-2649 |
Mrs. Elizabeth Kay Hill, MS, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 379 Shallowford Dr, Boiling Springs, SC 29316 Phone: 864-814-6940 |
Mrs. Robin Jean Jamison, MS-CCC/SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 165 Colfax Dr, Boiling Springs, SC 29316 Phone: 864-599-8138 |
Therapy Connections, Llc Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1291 Hanging Rock Rd, Boiling Springs, SC 29316 Phone: 864-431-1565 Fax: 864-578-3544 |
Mrs. Kendra Lea Mills, MA, CCC/SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 316 Blackberry Ln, Boiling Springs, SC 29316 Phone: 864-316-3626 |
Spartanburg School District 2 Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 700 Double Bridge Rd, Boiling Springs, SC 29316 Phone: 864-578-1231 |
Taylor Ballard, MCD, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 931 Thunder Gulch Dr, Boiling Springs, SC 29316 Phone: 828-817-4057 |
News Archive
Medical error is the third leading cause of death in the US after heart disease and cancer, say experts in The BMJ today.
Tolera Therapeutics, Inc., was granted orphan drug status by the United States Food and Drug Administration (FDA) for its initial lead candidate, TOL101, for prophylaxis of acute rejection of solid organ transplantation.
In the wake of Jade Goody's tragic story, the latest Cancer Research UK statistics reveal that there is hope on the horizon for cervical cancer.
Scientists at the Salk Institute for Biological Studies may have found one explanation for the puzzling variety in brain organization and function: mobile elements, pieces of DNA that can jump from one place in the genome to another, randomly changing the genetic information in single brain cells.
XenoPort, Inc. announced today preliminary top-line results of a Phase 2, randomized, crossover clinical trial that compared optimized treatment with either Sinemet (immediate-release levodopa/carbidopa) or XP21279 co-formulated with carbidopa (279/CD) in advanced Parkinson's disease patients with motor fluctuations.
› Verified 9 days ago